New Biomarkers, New Targets in Advanced NSCLC

Visit https://www.peervoice.com/VPK860 to view the entire programme with slides. After completing “New Biomarkers, New Targets in Advanced NSCLC”, participants will be able to: Explain the rationale for targeting TROP2 in patients with advanced non–small-cell lung cancer (NSCLC); Assess current clinical data for TROP2-directed antibody-drug conjugates (ADCs) in the management of advanced NSCLC that has progressed on current standards of care; and Formulate optimal, evidence-based treatment plans that maximise long-term outcomes for patients with advanced NSCLC.